Canopy Growth Corporation (CGC, Financial) experienced significant stock volatility, with the price dropping 5.14%. The stock is currently valued at $4.98 per share, with a trading volume of 3.25 million shares and a turnover rate of 3.83%. The price fluctuation registered at 8.29%.
According to Canopy Growth's recent financial report, the company generated $48.39 million in revenue, while reporting a net loss of $94.42 million, resulting in an earnings per share of -$1.17. Gross profit stood at $12.42 million, and the price-to-earnings ratio was recorded at -0.71.
In terms of analyst ratings, among 11 institutions providing ratings, 9% recommend buying, 55% suggest holding, and 36% advise selling the stock. The broader pharmaceutical sector, where Canopy Growth is categorized, saw a decline of 3.37%.
Some related stocks showed notable activities: Sunshine Biopharma Inc experienced a substantial gain, while Mira Pharmaceuticals and Intra-Cellular Therapies also saw significant increases. Meanwhile, Shuttle Pharmaceuticals Holdings and Flora Growth Corp witnessed high trading activity. Sunshine Biopharma, Gelteq Limited, and Mira Pharmaceuticals had large price swings.
Canopy Growth Corporation, headquartered in Smiths Falls, Canada, cultivates and sells medical and recreational cannabis through brands like Doja, 7ACRES, Tweed, and Deep Space. Its non-THC product line includes skincare products under Martha Stewart CBD and vaporizers by Storz & Bickel. The company's U.S. assets are held separately in an independent entity, Canopy USA.
